Evaluation Of The Efficacy Of Sichong Tablets In The Chronic Phase Of Deep Vein Thrombosis Based On "Internet +" Platform

Objectives: To build a "Internet +" DVT chronic phase management platform and explore the efficacy of Sichong Tablets in the treatment of deep vein thrombosis(DVT)chronic phase.Methods: From January 2019 to December 2019,a total of 84 patients with chronic DVT inpatients and outpatients in the Department of Peripheral Vascular Diseases,Affiliated Hospital of Shandong University of Traditional Chinese Medicine,were randomly divided into Sichong Tablets group and control group,with 42 patients in each group.Build and apply "Internet +" management platform for unified management,collect symptom quantification score,coagulation function index,venous recanalization index,quality of life scale score,safety index,etc.at the time of enrollment(before treatment)and 1 month later and 3 months later,and evaluate its efficacy.Results: 1.After 1 month of treatment,the effective rate was 90.48% in the Sichong Tablets group,which was higher than 88.10% in the control group.The effective rates of the two groups in March were 100%,but the significant recovery rate was 47.62% in the Sichong Tablets group.It was significantly higher than the control group by 21.43%(P<0.01).2.The symptoms quantitative scores in the two groups of patients at 1 and 3months after treatment were lower than before treatment,and the symptoms quantitative scores at 3 months after the treatment were lower than at 1month after treatment,and the symptoms quantitative points of 1 and 3months after treatment in the Sichong Tablets group are lower than the control group(P<0.01).3.After treatment,the Fib of the two groups of patients gradually decreased,and after 3 months of treatment,the Fib of the patients in the Sichong Tablets group was lower than that in the control group(P<0.01).4.Compared with those before treatment,the venous recanalization score decreased and the venous recanalization rate increased in the two groups of patients at 1 and 3 months after treatment(P<0.01);the venous recanalization score at 3 months after treatment was compared with 1 month after treatment Decreased and increased venous recanalization rate(P<0.01);after three months of treatment,the venous recanalization score of the Sichong Tablets group was lower than the control group,and the venous recanalization rate was higher than the control group(P<0.05).5.The quality of life scores of the two groups of patients at 1 month and3 months after treatment were higher than before treatment;the quality of life scores at 3 months after treatment were higher than 1 month after treatment;At 1 and 3 months after treatment,the quality of life scores of the patients in the Sichong Tablets group were higher than those in the control group(P<0.01).6.All patients did not suffer from liver and kidney damage and allergic reactions.Conclusions: Sichong Tablets can improve the clinical symptoms,reduce fibrinogen and promote venous recanalization,improve the clinical efficacy of patients with chronic DVT,and significantly improve the patient’s quality of life.